CNSP — CNS Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$6.27
+$0.38 (+6.41%)
CNS Pharmaceuticals Inc (CNSP) is a biotechnology company listed on NASDAQ. It is led by Rami Levin M.B.A., based in 2100 West Loop South, Houston, TX, United States, 77027, with about 8 employees. CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Net income was -$3.2M. CNSP currently screens at market cap $6.6M.
Use this CNSP page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CNSP quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CNSP SEC filings page. Lician reads the product cache first so this HTML stays unique to CNS Pharmaceuticals Inc even when a live quote feed is slow.
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
CNSP Key Statistics
Market Cap
$6.62M
Volume
8,553
Previous Close
$5.94
Day Range
$5.74 – $6.05
P/B Ratio
93.63
EPS
-$38.87
Revenue
$0.00
Net Income
-$14.86M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
8
CNSP Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$14.86M | -$18.85M | -$15.27M | -$14.50M |
| EPS (Diluted) | -$38.87 | -$12.51K | -$11.22 | -$16.50 |
Total Assets
$8.70M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$6.46M
Operating Cash Flow
-$17.11M
Free Cash Flow
$0.00
CNS Pharmaceuticals Inc Company Information
- President, CEO & Director
- Rami Levin M.B.A.
- Headquarters
- 2100 West Loop South, Houston, TX, United States, 77027
- Website
- cnspharma.com
- Phone
- 800 946 9185
- IPO / Founded
- 2019-11-08
- Sector
- Healthcare
- Industry
- Biotechnology